Stockpolly
Search
Delisting risk
MBRX · NASDAQ · Biotechnology

Moleculin Biotech (MBRX)

Developing Annamycin with cytarabine for relapsed or refractory acute myeloid leukemia.

$0.6913
Pre-market−0.01 (−0.86%)
At close$0.6973(+7.28%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
697677666888
Research & development374454344555
322222222222
General & administrative302220222222
Other expenses000000000000
Operating income−6−9−7−6−7−7−6−6−6−8−8−8
0−122−350−2−1923−50
Interest income000000000000
Interest expense000000000000
Other non-operating income01−2−23−50219−2350
Income before tax−6−10−5−4−11−2−6−8−2516−13−8
Net income from continuing operations−6−10−5−4−11−2−6−8−2516−13−8
Net income−6−10−5−4−11−2−6−8−2516−13−8
EPS, basic−$70.50−$128.15−$50.38−$42.46−$47.28−$48.71−$15.80−$12.30−$17.02$4.83−$3.54−$1.40
EPS, diluted−$70.50−$128.15−$50.38−$42.46−$47.28−$48.71−$15.80−$12.30−$17.02$4.83−$3.54−$1.40
Weighted average shares, basic000000011346
Weighted average shares, diluted000000011346
EBITDA−6−10−5−4−11−2−6−8−2516−13−8
Depreciation & amortization000000000000
EBIT−6−10−5−4−11−2−6−8−2516−13−8